⭐️Results of etrasimod in UC proctitis from ELEVATE trials

Great to finally have trials with advanced therapies including proctitis

academic.oup.com/ecco-jcc/advan…

1/3 of IBD patients in biochemical remission have IBS-like symptoms, and those with altered anatomy require careful consideration of differentials.

An excellent paper on abdominal pain and IBS-like symptoms in IBD! 👇Andrew Ong
doi.org/10.1111/apt.17…

#IBD #ibs #GITwitter

Are we Excited about ETRASIMOD?

Or is it more Eh..trasimod??

Let's take a close look at the recently published paper evaluating the effectiveness of the Sphingosine-1-Phosphate Receptor Modulator ETRASIMOD in patients with ulcerative colitis

🧵🧵🧵

🚨 Check out our review on persistent #GI symptoms in #IBD in remission roypounder.apt

Great collaborative effort ⬇️

🔥 Our latest article on persistent #GI symptoms in #IBD in remission', just published in@APandT
➡️ A step-by-step approach: lnkd.in/eZzRp8y5

Arta Aliu Daniel Keszthelyi MD PhD Ashkan Rezazadeh MD
The Bottom Line IBD Jean-Frederic Colombel Hans Törnblom Marieke Pierik a
#GI Twitter #MedTwitter

JAK-STAT pathways can be complex to understand, gaining insight into their functions helps us comprehend the consequences of their blockade.

Bearing this in mind, I have done a summary attempting to synthesize this complexity focusing on #IBD therapies, I hope it proves useful.…

Upadacitinib for Crohn's disease

• data from Edinburgh and Exeter
• n=93 with median 25w follow-up
• effective in highly refractory cohort

See 👇 for figures and link Frontline Gastro

After losing response to first line agent, 2nd agents have ⬇️ efficacy in CD. Some think 1st agent changes biology.

I don't. I think it selects refractory patients. CGH supports that effective agents are effective 2nd.

▶️UPA works in CD. Done.

cghjournal.org/article/S1542-…

The impact of the adherence to Mediterranean diet and physical activity on #IBD prognosis

⭐️Healthy lifestyle was associated with:

- Lower risk of mod-severe relapses (aHR, 0.250; 0.093-0.670)
- Steroids use (aHR 0.292; 0.103-0.828)
- Lower risk of mod-severe relapses (aHR…

#ChatGPT for patients with #IBD versus Y-ECCO guidelines, exploring accuracy and completeness
academic.oup.com/ecco-jcc/advan… Martina Sciberras pierre ellul Mariangela Allocca Federica Gionata Fiorino, MD, PhD Bram Verstockt marietta iacucci Joana Torres Fernando Magro Valerie Fenech

🎆 The Journal of Crohn’s and Colitis Journal of Crohn's and Colitis podcast is back!

Fantastic to have this conversation with IUS rising 💫 Michael Todd Dolinger, MD MBA from Mount Sinai Health System on his latest JCC article about the role in predicting endoscopic remission in children with ileal CD

Thanks 🙏🏻Soon out!

Congratulate Shrinivas Bishu

A brilliant research mind
A superb doctor
A cherished friend
A great dad
And now he has an endowed chair

🚨Strategies for targeting cytokines in #IBD Nature Rev Immunol

Timely, comprehensive and elegant state of the art by #MarkusNeurath

Y-ECCO Florian Rieder Fernando Gomollón Irina Blumenstein Aline Charabaty, MD, FACG, AGAF Gianluca Pellino Bram Verstockt Peter Higgins John Ding MD PhD Raja Atreya

Increased risk of liver #cirrhosis in #IBD

🇩🇰 registry (1998-2018)

N=495,220➡️ 2741 cirrhosis

⭐️ Cirrhosis risk IBD vs non-IBD (aHR 1.84, 1.64-2.04)

Leading etiology
1) NAFLD 51.6%
2) Alcohol 39%

Risk ⬆️ if:
IBD diagnosed =<40 y/o and in CD vs UC

medrxiv.org/content/10.110…

Exciting News! 🎉 #JCC is thrilled to announce the launch of its X account dedicated to disseminating accepted manuscripts in the #IBD field! Authors are encouraged to include a graphical abstract with their revised manuscripts for enhanced visibility. Join us today!

🔺 #Microbiome composition 🔗to #IBD Location (ileal vs colonic CD/UC vs L3CD)

🔺TNFi (but not VDZ or UST) shift microbiome composition, ⬇️ dysbiosis, ⬆️load

🔺TNFi > VDZ in pts w Bacteroides2

✅Predictive model of Rx response👇🏽

Gastroenterology doi.org/10.1053/j.gast…

Happy to share our review published in The Lancet! Enjoyed working on this international collaboration. SarahStreettMD Stanford Div. of GI & Hepatology W Ray Kim. Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation sciencedirect.com/science/articl…

Shrinivas Bishu, guest speaker Pitt Division of GI, Hepatology & Nutrition IBD U.N.I.T.E (Unify, Network, Inspire, Treat, & Educate).

World-class lesson: distilling IBD via terrible drawing😅(his quote)

Beatriz Gros unsurprisingly noted😍 can you even have an introductory talk w/o IBD-eii.com?

If you are a GI fellow, or anyone interested in #IBD

The ibd-eii.com by Beatriz Gros is a must.

Encyclopedic catalogue of IBD medication trials…..by year…..with links!

Years ago, I shared the first #IBD timeline here w the names of relevant studies

With the advent of the web, updates of those slides paused
⭐️at #ECCO2024 I noticed it could still be useful. I did an updated version (incl 2024!)
Hope it helps!
Happy to add/change anything